Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

@article{Barten2006GammasecretaseIF,
  title={Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.},
  author={Donna M. Barten and Jere E. Meredith and Robert C. Zaczek and John G Houston and Charles F. Albright},
  journal={Drugs in R&D},
  year={2006},
  volume={7 2},
  pages={
          87-97
        }
}
The amyloid hypothesis, which states that beta-amyloid (Abeta) aggregates cause the onset and progression of Alzheimer's disease (AD), is a leading proposal to explain AD aetiology. Based on this hypothesis, compounds that inhibit gamma-secretase, one of the enzymes responsible for forming Abeta, are potential therapeutics for AD. Preclinical studies clearly establish that gamma-secretase inhibitors can reduce brain Abeta in rodent models. The initial investigation of the effects of a gamma… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…